What is the mechanistic evidence that SGLT2 inhibitors confer cardiovascular benefit independent of glucose lowering? List the key supporting papers with PMIDs.

Evidence from preclinical and clinical studies indicates that SGLT2 inhibitors (SGLT2i) confer cardiovascular protection through mechanisms independent of glucose lowering, including direct modulation of cardiac ion transporters, metabolic reprogramming toward ketone oxidation, and suppression of systemic inflammation and sympathetic activity. Notably, multiple studies using SGLT2-knockout (KO) models confirm that these benefits persist in the absence of the SGLT2 protein (Direct, High; PMID: 38118414, PMID: 39046464).

Evidence for SGLT2-Independent Effects

• Absence of Cardiac SGLT2 Expression: Comprehensive single-cell transcriptomic analyses in humans and mice across healthy, fetal, and failing heart states demonstrate that SLC5A2 (the gene encoding SGLT2) is not expressed in any cardiac cell type, including cardiomyocytes, fibroblasts, or endothelial cells (Direct, High; PMID: 40065073).
• Protection in SGLT2-Knockout Models: In murine models of heart failure (HF) and myocardial infarction, SGLT2i such as empagliflozin and dapagliflozin significantly improved cardiac function, reduced fibrosis, and attenuated hypertrophy in SGLT2-KO mice to the same degree as in wild-type mice (Direct, High; PMID: 38118414, PMID: 39046464).

Off-Target Inhibition of Sodium-Hydrogen Exchanger 1 (NHE1)

• NHE1 and Ion Homeostasis: SGLT2i directly bind to and inhibit the cardiac Na+/H+ exchanger 1 (NHE1). This inhibition reduces cytosolic $Na^+$ and $Ca^{2+}$ concentrations while increasing mitochondrial $Ca^{2+}$, thereby preventing ion overload and improving mitochondrial energetics (Direct, High; PMID: 27752710, PMID: 29197997).
• Anti-fibrotic Signaling: In human atrial fibroblasts, empagliflozin inhibits the NHE1 signaling pathway, which subsequently attenuates the PLC/IP3 receptor/ER $Ca^{2+}$ signaling cascade, leading to reduced collagen production and migration (Direct, High; PMID: 36747205).
• NHE1-NO Axis: Experimental evidence suggests that the cardioprotective effects of empagliflozin are mediated through a NHE1-NO pathway. Chronic inhibition of nitric oxide (NO) synthesis completely abrogates the protective effects of empagliflozin in heart failure models (Direct, High; PMID: 39046464).

Metabolic Reprogramming and Ketone Body Oxidation

• Shift in Fuel Utilization: SGLT2i increase hepatic ketogenesis, leading to elevated circulating levels of $\beta$-hydroxybutyrate ($\beta$OHB). $\beta$OHB serves as a "thrifty fuel" that is more efficiently oxidized by the energy-starved failing heart, improving ATP production and cardiac contractility (Direct, High; PMID: 32613148, PMID: 40069113).
• Requirement for Ketone Oxidation: The beneficial effects of empagliflozin on cardiac contractility were attenuated in mice lacking the ketogenic enzyme D-$\beta$-hydroxybutyrate-dehydrogenase-1 (BDH1), suggesting that enhanced ketone oxidation is a requisite component of SGLT2i-mediated cardioprotection (Direct, High; PMID: 40069113).

Anti-inflammatory and Anti-senescence Mechanisms

• NLRP3 Inflammasome Suppression: SGLT2i modulate the NLRP3 inflammasome activity in human macrophages by increasing $\beta$OHB levels and decreasing insulin and uric acid levels, which reduces the secretion of pro-inflammatory cytokines like IL-1$\beta$ (Direct, High; PMID: 32358544).
• STAT1-STING Axis: Empagliflozin protects against heart failure with preserved ejection fraction (HFpEF) by inhibiting the senescence-associated STAT1-STING signaling pathway, thereby delaying cardiomyocyte aging and reducing the senescence-associated secretory phenotype (Direct, High; PMID: 39044275).

Sympathetic and Hemodynamic Regulation

• Central Sympathoinhibition: Dapagliflozin crosses the blood-brain barrier to target the paraventricular nucleus (PVN) and nucleus tractus solitarius (NTS) in the hypothalamus, where it suppresses pre-sympathetic neurons, leading to a reduction in systemic sympathetic outflow and blood pressure without a compensatory increase in heart rate (Direct, High; PMID: 41658515).
• Myocardial Iron Repletion: Empagliflozin treatment is associated with increased myocardial iron content (estimated by MRI-T2* mapping), which correlates with reverse LV remodeling and improved peak oxygen consumption in patients with HF (Direct, High; PMID: 39196095, PMID: 39907687).

What is the role of the NHE1-NO axis in mediating the cardiovascular protective effects of empagliflozin in heart failure?

How do ketone body oxidation levels and $\beta$-hydroxybutyrate concentrations change in response to chronic versus acute SGLT2 inhibition?

What specific hypothalamic pathways and neuronal subtypes are involved in the central sympatholytic effects of dapagliflozin?

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:38118414 — ** Absence of Cardiac SGLT2 Expression: Comprehensive single-cell transcriptomic analyses in humans and mice across...*
  Failed: mechanism,conclusion — The paper confirms the absence of SGLT2 protein in the heart using Western blot, but it does not perform a 'comprehensive single-cell transcriptomic analysis' in fetal states or across humans as the claim asserts.
• PMID:36731341 — This inhibition reduces cytosolic $Na^+$ and $Ca^{2+}$ concentrations while increasing mitochondrial $Ca^{2+}$, thereby ...
  Failed: conclusion — While the paper confirms reduction of Na+ and improved energetics, it does not measure or report changes in cytoplasmic or mitochondrial Ca2+ concentrations as asserted in the claim.
• PMID:39680452 — $\beta$OHB serves as a "thrifty fuel" that is more efficiently oxidized by the energy-starved failing heart, improving A...
  Failed: conclusion — The paper explicitly states in its discussion that its results (using stable isotopes) indicate substrate preference but do not allow direct quantification of efficiency or absolute ATP production.
• PMID:42099788 — ** NLRP3 Inflammasome Suppression: SGLT2i modulate the NLRP3 inflammasome activity in human macrophages by increasi...*
  Failed: mechanism,conclusion — The paper does not investigate or report data on beta-hydroxybutyrate (betaOHB) or insulin levels; its findings are focused on elaidic acid accumulation and the NF-kB/NLRP3 pathway.

Unverified Table Citations

The following table rows had citations that could not be verified:

• PMID: 31924211 — Dapagliflozin inhibits STAT3 signaling: attenuated cardiac fibrosis — Dapagliflozin regulates macrophage polarization vi...
  Failed: conclusion — The paper cites another study (reference 50) for the STAT3 mechanism rather than providing its own experimental data or substantive discussion of STAT3; the provided text focuses on ion channels (NHE1, NCX) and calcium.